Thomas Ruhstaller1, Anita Giobbie-Hurder2, Marco Colleoni3, Maj-Britt Jensen4, Bent Ejlertsen4, Evandro de Azambuja5, Patrick Neven6, István Láng7, Erik Hugger Jakobsen8, Laurence Gladieff9, Hervé Bonnefoi10, Vernon J Harvey11, Simon Spazzapan12, Carlo Tondini13, Lucia Del Mastro14, Corinne Veyret15, Edda Simoncini16, Lorenzo Gianni17, Christoph Rochlitz18, Elena Kralidis19, Khalil Zaman20, Jacek Jassem21, Martine Piccart-Gebhart5, Angelo Di Leo22, Richard D Gelber2,23,24, Alan S Coates25,26, Aron Goldhirsch3,26, Beat Thürlimann1,26, Meredith M Regan2,23. 1. 1 Kantonsspital St Gallen, St Gallen, Switzerland. 2. 2 Dana-Farber Cancer Institute, Boston, MA. 3. 3 European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy. 4. 4 Rigshospitalet, Copenhagen, Denmark. 5. 5 Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium. 6. 6 KU Leuven, Leuven, Belgium. 7. 7 National Institute of Oncology, Budapest, Hungary. 8. 8 Lillebaelt Hospital, Vejle, Denmark. 9. 9 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France. 10. 10 Université de Bordeaux, Bordeaux, France. 11. 11 Auckland City Hospital, Auckland, New Zealand. 12. 12 CRO National Cancer Institute, Aviano, Italy. 13. 13 Ospedale Papa Giovanni XXIII, Bergamo, Italy. 14. 14 Ospedale Policlinico San Martino, Genoa, Italy. 15. 15 Centre de Cancérolgie Henri Becquerel, Rouen, France. 16. 16 ASST Spedali Civili di Brescia, Brescia, Italy. 17. 17 Ospedale Infermi di Rimini, AUSL della Romagna, Ravenna, Italy. 18. 18 Universitätsspital, Basel, Switzerland. 19. 19 Kantonsspital, Aarau, Switzerland. 20. 20 University Hospital Vaud University Hospital Center, Lausanne, Switzerland. 21. 21 Medical University of Gdansk, Gdansk, Poland. 22. 22 Hospital of Prato-AUSL Toscana Centro, Prato, Italy. 23. 23 Harvard Medical School, Boston, MA. 24. 24 Harvard TH Chan School of Public Health and Frontier Science and Technology Research Foundation, Boston, MA. 25. 25 University of Sydney, Sydney, NSW, Australia. 26. 26 International Breast Cancer Study Group, Bern, Switzerland.
Abstract
PURPOSE: Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after diagnosis. We analyzed long-term follow-up (LTFU) of efficacy outcomes and adverse events in the Breast International Group (BIG) 1-98 study reported after a median follow-up of 12.6 years. PATIENTS AND METHODS: BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) and their sequences (2 years of one treatment plus 3 years of the other) for postmenopausal women with endocrine-responsive early breast cancer. When pharmaceutical company sponsorship ended at 8.4 years of median follow-up, academic partners initiated an observational, LTFU extension collecting annual data on survival, disease status, and adverse events. Information from Denmark was from the Danish Breast Cancer Cooperative Group Registry. Intention-to-treat analyses are reported. RESULTS: Of 8,010 enrolled patients, 4,433 were alive and not withdrawn at an LTFU participating center, and 3,833 (86%) had at least one LTFU report. For the monotherapy comparison of letrozole versus tamoxifen, we found a 9% relative reduction in the hazard of a disease-free survival event with letrozole (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.01). HRs for other efficacy end points were similar to those for disease-free survival. Efficacy of letrozole versus tamoxifen for contralateral breast cancer varied significantly over time (0- to 5-, 5- to 10-, and > 10-year HRs, 0.62, 0.47, and 1.35, respectively; treatment-by-time interaction P = .005), perhaps reflecting a longer carryover effect of tamoxifen. Reporting of specific long-term adverse events seemed more effective with national registry than with case-record reporting of clinical follow-up. CONCLUSION: Efficacy end points continued to show trends favoring letrozole. Letrozole reduced contralateral breast cancer frequency in the first 10 years, but this reversed beyond 10 years. This study illustrates the value of extended follow-up in trials of luminal breast cancer.
RCT Entities:
PURPOSE:Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after diagnosis. We analyzed long-term follow-up (LTFU) of efficacy outcomes and adverse events in the Breast International Group (BIG) 1-98 study reported after a median follow-up of 12.6 years. PATIENTS AND METHODS: BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) and their sequences (2 years of one treatment plus 3 years of the other) for postmenopausal women with endocrine-responsive early breast cancer. When pharmaceutical company sponsorship ended at 8.4 years of median follow-up, academic partners initiated an observational, LTFU extension collecting annual data on survival, disease status, and adverse events. Information from Denmark was from the Danish Breast Cancer Cooperative Group Registry. Intention-to-treat analyses are reported. RESULTS: Of 8,010 enrolled patients, 4,433 were alive and not withdrawn at an LTFU participating center, and 3,833 (86%) had at least one LTFU report. For the monotherapy comparison of letrozole versus tamoxifen, we found a 9% relative reduction in the hazard of a disease-free survival event with letrozole (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.01). HRs for other efficacy end points were similar to those for disease-free survival. Efficacy of letrozole versus tamoxifen for contralateral breast cancer varied significantly over time (0- to 5-, 5- to 10-, and > 10-year HRs, 0.62, 0.47, and 1.35, respectively; treatment-by-time interaction P = .005), perhaps reflecting a longer carryover effect of tamoxifen. Reporting of specific long-term adverse events seemed more effective with national registry than with case-record reporting of clinical follow-up. CONCLUSION: Efficacy end points continued to show trends favoring letrozole. Letrozole reduced contralateral breast cancer frequency in the first 10 years, but this reversed beyond 10 years. This study illustrates the value of extended follow-up in trials of luminal breast cancer.
Authors: M Gnant; I Sestak; M Filipits; M Dowsett; M Balic; E Lopez-Knowles; R Greil; P Dubsky; H Stoeger; M Rudas; R Jakesz; S Ferree; J W Cowens; T Nielsen; C Schaper; C Fesl; J Cuzick Journal: Ann Oncol Date: 2015-05-01 Impact factor: 32.976
Authors: Marloes G M Derks; Erik J Blok; Caroline Seynaeve; Johan W R Nortier; Elma Meershoek-Klein Kranenbarg; Gerrit-Jan Liefers; Hein Putter; Judith R Kroep; Daniel Rea; Annette Hasenburg; Christos Markopoulos; Robert Paridaens; Jan B E Smeets; Luc Y Dirix; Cornelis J H van de Velde Journal: Lancet Oncol Date: 2017-07-18 Impact factor: 41.316
Authors: James P Morden; Isabel Alvarez; Gianfilippo Bertelli; Alan S Coates; Robert Coleman; Lesley Fallowfield; Jacek Jassem; Stephen Jones; Lucy Kilburn; Per E Lønning; Olaf Ortmann; Claire Snowdon; Cornelis van de Velde; Jørn Andersen; Lucia Del Mastro; David Dodwell; Stig Holmberg; Hanna Nicholas; Robert Paridaens; Judith M Bliss; R Charles Coombes Journal: J Clin Oncol Date: 2017-05-03 Impact factor: 44.544
Authors: Clifford A Hudis; William E Barlow; Joseph P Costantino; Robert J Gray; Kathleen I Pritchard; Judith-Anne W Chapman; Joseph A Sparano; Sally Hunsberger; Rebecca A Enos; Richard D Gelber; Jo Anne Zujewski Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes Journal: Lancet Oncol Date: 2010-11-17 Impact factor: 41.316
Authors: Meredith M Regan; Karen N Price; Anita Giobbie-Hurder; Beat Thürlimann; Richard D Gelber Journal: Breast Cancer Res Date: 2011-05-26 Impact factor: 6.466
Authors: Jack Cuzick; Ivana Sestak; Simon Cawthorn; Hisham Hamed; Kaija Holli; Anthony Howell; John F Forbes Journal: Lancet Oncol Date: 2014-12-11 Impact factor: 41.316
Authors: Clara Inkyung Lee; Siew Kee Low; Ricardo Maldonado; Peter Fox; Bavanthi Balakrishnar; Sally Coulter; Peter de Bruijn; Stijn L W Koolen; Bo Gao; Jodi Lynch; Nicholas Zdenkowski; Rina Hui; Christopher Liddle; Ron H J Mathijssen; Nicholas Wilcken; Mark Wong; Howard Gurney Journal: Breast Date: 2020-10-21 Impact factor: 4.380
Authors: A Z de Boer; N A de Glas; P J Marang-van de Mheen; O M Dekkers; S Siesling; L de Munck; K M de Ligt; G J Liefers; J E A Portielje; E Bastiaannet Journal: Br J Surg Date: 2020-04-07 Impact factor: 6.939
Authors: Ye Won Jeon; Sun Hyong You; Jong Eun Lee; Hyun Jo Youn; Woosung Lim; Jai Hong Han; Chan Heun Park; Yong Seok Kim Journal: Breast Cancer Res Treat Date: 2019-09-06 Impact factor: 4.872